A Phase 4 interventional study of Aspirin 81 mg and Aspirin 162 mg in Hypertensive Disorders of Pregnancy, Preeclampsia and Gestational Hypertension, sponsored by Ohio State University. Recruiting at 20 sites in United States. Open to female participants aged 14 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Ohio State University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing aspirin in Pre-Eclampsia — 18 open to participants now, 22 under way, 5 of them phase 3. Aspirin · Pre-Eclampsia.
Among the 52 studies testing aspirin in Pre-Eclampsia, this one has the largest planned enrollment, is one of 5 that started in 2024, is one of 16 in phase 4, reaches primary completion later than 17 of the 21 other live ones, and was the 43rd registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →18 of the 52 studies testing aspirin in Pre-Eclampsia are open now, in 11 countries. Recruiting first, the newest first:
University of Calgary · Sites in Belgium, Canada, Denmark and 4 more countries
Ages 18+ · Women only
Medicare Hospital (Pvt) Limited · Sites in Pakistan
Ages 18–45 · Women only
NYU Langone Health · Sites in United States
Ages 18–50 · Women only
Thomas Jefferson University · Sites in United States
Ages 16–55 · Women only
University of Pennsylvania · Sites in United States
Ages 18–45 · Women only
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 14 Years to 35 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 13 · Phase 4 16
First in 2001; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,742 is above the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 235 across the 52 interventional studies. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 52 have an industry lead sponsor. The 10 most frequent:
Ohio State University is the lead sponsor of 664 studies on the registry; 149 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.
11 studies in Pre-Eclampsia by Ohio State University: 4 open now, 4 under way, none of them phase 3. Of 7 finished, 4 (57%) have results posted.
Among the 11 studies in Pre-Eclampsia by Ohio State University, this one is one of 2 that started in 2024, is one of 5 in phase 4, and was the 9th registered.
Ohio State University’s Pre-Eclampsia studies by the year they started, since 2003.
6 of the studies testing aspirin in Pre-Eclampsia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05924971MemorialCare Health SystemAspirin for Postpartum Patients With Preeclampsia | 2026-12 |
| NCT04479072University of ChicagoAspirin and Preeclampsia | 2026-12-01 |
| NCT07373756Dr. Sunita PunRandomized Controlled Study to Compare Efficacy of Aspirin 75mg and 150mg In the Prevention of Preeclampsia In High Risk Pregnant Women | 2026-12-31 |
| NCT06281665Malamo CountourisTreatment With Aspirin After Preeclampsia: TAP Trial | 2027-01-01 |
| NCT07041385Shalamar HospitalComparing the Efficacy of 75mg Versus 150mg Aspirin for the Prevention of Preeclampsia in High-Risk Pregnant Women | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 52 studies testing aspirin in Pre-Eclampsia, from their registry updates:
Among Ohio State University’s 11 in Pre-Eclampsia:
This tab as a report to print or save as PDF → With an account.
The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.
Hypertensive disorders of pregnancy (HDP), such as preeclampsia (PE) and gestational hypertension (gHTN), occur in \~15% of pregnant individuals, disproportionately affect self-identified non-Hispanic Black individuals (with the understanding that race is a socially defined construct and the inequity is related to social determinants of health), are increasing in frequency, and are associated with short- and long-term maternal and neonatal morbidities and mortality. There are currently no available therapeutics to treat individuals with HDP; thus, developing interventions for the prevention of HDP is of substantial public health significance. The U.S. Preventive Services Task Force (USPSTF) and other professional societies recommend or endorse the use of aspirin for prevention of HDP in individuals at high or moderate risk. However, there is great uncertainty regarding optimal dosing, whether there is heterogeneity of effectiveness of aspirin in reducing the risk of HDP among different populations, and what factors are associated with adherence.
The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing HDP, and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits. The trial will achieve the following specific aims:
Specific Aim 1: To compare the frequency of HDP (primary outcome), as well as other important secondary outcomes (gHTN, PE, preterm PE, PE-related adverse outcomes, aspirin-related safety outcomes, and patient-reported outcomes related to maternal health, pregnancy, and childbirth experiences) between the two aspirin treatment arms.
Specific Aim 2: To compare the gestational age at birth and the frequency of adverse perinatal outcomes (preterm birth, perinatal death, small-for-gestational-age birth, neonatal intensive care unit admission, and complications of prematurity), as well as patient-reported outcomes related to maternal-infant bonding between the two aspirin treatment arms.
Specific Aim 3: To use quantitative and qualitative analyses to elucidate facilitators and barriers associated with adherence to aspirin therapy in at-risk individuals during pregnancy in order to facilitate future implementation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A consisting of 81mg of aspirin (1 pill of 81mg \& 1 matching placebo) daily
Drug: Aspirin 81 mg
Treatment B consisting of 162mg of aspirin (2 pills, each of 81mg) daily
Drug: Aspirin 162 mg
Participants will be assigned to 81mg Aspirin
Participants will be assigned to 162mg Aspirin
Hypertensive Disorder of Pregnancy (HDP)
HDP defined as preeclampsia or antepartum gHTN based on ACOG criteria
Time frame: From >20 weeks gestation until hospital discharge following delivery, up to 22 weeks
Preeclampsia
preeclampsia based on ACOG criteria
Time frame: From >20 weeks gestation until hospital discharge following delivery, up to 22 weeks
Preterm preeclampsia
Preeclampsia per ACOG criteria with delivery \< 37 weeks'
Time frame: From >20 weeks and ≤ 36 weeks 6 days, up to 17 weeks
Postpartum preeclampsia
Postpartum preeclampsia per ACOG criteria
Time frame: From delivery weeks till 6 weeks postpartum; 6 weeks
Gestational hypertension
Gestational hypertension per ACOG criteria
Time frame: From >20 weeks until onset of labor, up to 22 weeks
Severe maternal morbidity
Need for intensive care, maternal admission to a hospital within the first 42 days postpartum for obstetric complications, or blood product transfusion
Time frame: From randomization up to 6 weeks postpartum, up to 48 weeks
Core preeclampsia outcomes
Composite and individual maternal outcomes (Mortality, Eclampsia, Stroke, Cortical blindness, Retinal detachment, Pulmonary edema, Acute kidney injury, Liver capsule hematoma, Placental abruption, Postpartum hemorrhage, Elevated liver enzymes, Thrombocytopenia, ICU admission, Mechanical ventilation)
Time frame: From randomization up to 6 weeks postpartum, up to 48 weeks
Bleeding complications (maternal)
Antepartum bleeding and Placental abruption
Time frame: From randomization till delivery up to 36 weeks, up to 36 weeks
Bleeding complications (maternal)
Postpartum hemorrhage
Time frame: From delivery till hospital discharge, up to 1 week
Adherence to aspirin
pill count
Time frame: From randomization until last day of medication intake, up to 42 weeks
Preterm birth
Delivery \<37 weeks
Time frame: At time of delivery
Gestational age at birth
Gestational age in weeks at time of delivery
Time frame: At time of delivery
Core offspring/neonatal outcomes
Composite and individual neonatal outcomes (Stillbirth, SGA, Neonatal mortality, Neonatal seizures, Admission to NICU, Respiratory support)
Time frame: up to 6 weeks post-delivery
Rate of SGA
Rate of birthweight \<10th percentile
Time frame: At time of birth
Bleeding complications (neonatal)
Any neonatal intraventricular or intracranial hemorrhage
Time frame: Up to 6 weeks post-delivery
Complications of prematurity and neonatal safety outcomes
Composite of RDS, Grade III-IV IVH, PVL, Stage 2/3 NEC, BPD, Stage III or higher ROP, or early onset sepsis
Time frame: Up to 6 weeks post-delivery
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Jan 2029, 50 months after the start.
Of 35 phase 4 interventional studies under Pre-Eclampsia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 35. This study's planned 50 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin